Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU)/Rituxan, met its primary...
Pfizer Inc. announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab),...
Visus Therapeutics reported positive topline results from its Phase III pivotal BRIO-I trial for the treatment of Presbyopia. BRIO-I met the pre-specified primary study endpoints agreed upon with the US-FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, brimochol PF, over both active comparators carbachol and brimonidine monotherapies. Brimochol PF demonstrated highly statistically significant improvements in near and distance binocular visual acuity at multiple timepoints over carbachol and brimonidine
Pfizer has announced that the comparative, confirmatory REFLECTIONS B538-02 study of PF 06410293(adalimumab biosimilar) met its primary objective by demonstrating...
Pfenex Inc. has announced that the FDA has approved the new drug application (�NDA�) for PF 708 submitted under the...
Sandoz, a Novartis company and a global leader in biosimilars, announced that it has acquired from Pfizer the rights for...
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients.
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.
Pfizer announced at the American Society of Hematology Annual Meeting that the REFLECTIONS B328-06 study, a comparative safety and efficacy...
Medtronic plc, announced positive clinical trial safety and efficacy results for Sphere-360 , an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib)